Synthesize heterogeneous biological knowledge via representation learning for Alzheimer’s disease drug repurposing
Developing drugs for treating Alzheimer’s disease has been extremely challenging and costly due to limited knowledge of underlying mechanisms and therapeutic targets. To address the challenge in AD drug development, we developed a multi-task deep learning pipeline that learns biological interactions...
Saved in:
Published in | iScience Vol. 26; no. 1; p. 105678 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
20.01.2023
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Developing drugs for treating Alzheimer’s disease has been extremely challenging and costly due to limited knowledge of underlying mechanisms and therapeutic targets. To address the challenge in AD drug development, we developed a multi-task deep learning pipeline that learns biological interactions and AD risk genes, then utilizes multi-level evidence on drug efficacy to identify repurposable drug candidates. Using the embedding derived from the model, we ranked drug candidates based on evidence from post-treatment transcriptomic patterns, efficacy in preclinical models, population-based treatment effects, and clinical trials. We mechanistically validated the top-ranked candidates in neuronal cells, identifying drug combinations with efficacy in reducing oxidative stress and safety in maintaining neuronal viability and morphology. Our neuronal response experiments confirmed several biologically efficacious drug combinations. This pipeline showed that harmonizing heterogeneous and complementary data/knowledge, including human interactome, transcriptome patterns, experimental efficacy, and real-world patient data shed light on the drug development of complex diseases.
[Display omitted]
•Our study aims to find AD drugs from biological interactome and structural associations•Our ranking model utilized multi-level drug evidence for drug prioritization•Our predicted drug combinations can reduce Aβ-induced ROS production in neuronal cells
Drugs; Neuroscience; Artificial intelligence |
---|---|
Bibliography: | These authors contributed equally Lead contact |
ISSN: | 2589-0042 2589-0042 |
DOI: | 10.1016/j.isci.2022.105678 |